Gemin X Pharmaceuticals

Gemin X Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, with research operations in Montréal, Canada, that develops targeted cancer therapeutics focused on reinitiating programmed cell death. The organization's primary clinical drug pipeline includes obatoclax, a pan Bcl-2 inhibitor targeting small cell lung cancer, and GMX1777, a novel inhibitor of NAD+ synthesis. Backed by investors such as Caxton Advantage Life Sciences Fund and Sanderling Ventures, the firm secured an $8 million Series E financing round in 2010 to support Phase 3 trial preparations. Under the leadership of Chief Executive Officer Peter R. Dolan, the enterprise was acquired by Cephalon in March 2011 for an upfront $225 million payment, alongside $300 million in potential regulatory and sales milestones. Gemin X Pharmaceuticals was originally founded during 1998 as an academic research spin-out from McGill University.